SEC Form 4 · accession 0000899243-18-018500
XERIS PHARMACEUTICALS INC · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Erland Johnson
Officer — See Remarks
Period of report
Jun 25, 2018
Accepted (ET)
Jun 27, 2018 · 8:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001346302
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 25, 2018 | C | 2,245 | — | A | 2,245 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C Preferred StockF1 | — | Jun 25, 2018 | C | 4,000 | D | — | — | Common Stock | 2,245 | 0 | D |
Explanation of responses
- F1Each share of Preferred Stock automatically converted into Common Stock, for no additional payment or consideration, on a 1.78112-for-1 basis at the closing of the Issuer's initial public offering on June 25, 2018 and had no expiration date.
Remarks
Senior Vice President Clinical Development, Quality Assurance, and Medical Affairs